High expression levels of METTL3 are predictive of an inferior outcome for NB patients and METTL3 is expressed in both ALT+ and MYCN-amplified (MNA) high-risk NB tumors, suggesting it may have broader relevance (Vaid et al, 2024). Here, MYCN is linked to neuroblastoma.